Drugs for Rheumatoid Arthritis: Global Markets to 2022

Drugs for Rheumatoid Arthritis: Global Markets to 2022

  • March 2018 •
  • 182 pages •
  • Report ID: 5361406 •
  • Format: PDF
Report Scope:
This research report categorizes the drugs for rheumatoid arthritis market by type. Product type include disease modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs and corticosteroids.

Report Includes:
- 95 data tables
- An overview of the global rheumatoid arthritis drugs market
- Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Identification of segments with high growth potential and their future applications
- Explanation of major drivers and regional dynamics of the market and current trends within the industry
- Detailed profiles of major vendors in the market, including AbbVie Inc., Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG and Pfizer Inc.

Summary
Global drugs for rheumatoid arthritis market is currently in a very crucial phase of development. There is mounting pressure to reduce drug development costs, and provide drugs to treat rheumatoid arthritis which is widely prevalent among elderly population globally. At the same time, emerging markets growth, sedentary lifestyles, rapid urbanization, rising ageing population, technological advances aiding research and development activities, diagnosis and treatment is driving the demand of drugs for rheumatoid arthritis market.

The drugs for rheumatoid arthritis market reached a value of nearly REDACTED in 2017 and is expected to grow at a compound annual growth rate (CAGR) of REDACTED to nearly REDACTED by 2020. The drugs for rheumatoid arthritis market is concentrated with a few large players dominating the market.

Major players in the market are AbbVie, F. Hoffman-La Roche AG, Amgen, Pfizer and Bristol- Myers Squibb and others.

DMARDs accounted for the largest share of the drugs for rheumatoid arthritis market in 2017 at REDACTED. The highest growth is projected to come from Corticosteroids, which is forecasted to grow at a CAGR of REDACTED. Major factors included economic growth, technological developments and rapid growth inelderly population globally.

North America is the largest drugs for rheumatoid arthritis market, accounting for REDACTED of the globalmarket. It was followed by South America and Western Europe region. Going forward, South America is expected to witness the fastest growth in the drugs for rheumatoid arthritis market, estimated at growat a CAGR of REDACTED, followed by North America, which is expected to grow at a CAGR of REDACTED.

The USA is the largest market in terms of value and in the drugs for rheumatoid arthritis market. Brazil and China are forecasted to have the fastest growth, growing at a CAGR of REDACTED and REDACTED, respectively.The market is challenged by restraints such as decline in patent expiration of drugs, high medicationcosts and lack of research and development projects.

Scope of Report
This research report categorizes the drugs for rheumatoid arthritis market by type. Product type include disease modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs and corticosteroids.

Reasons for Doing This Study
Political support in form of investments in research and development, tax waivers and subsidies offered to the manufacturers as well as the users by the national and state governments has led to an increase in the demand of drugs for rheumatoid arthritis market globally. Global industry leaders and large organizations see an expanded role for technological breakthrough, internet penetration, and mobile applications in the drugs for rheumatoid arthritis industry.

The global drugs for rheumatoid arthritis market is growing due to rise in aging population, growing awareness, increasing health care reforms and constant research and development in rheumatoid arthritis drugs by pharmaceutical companies in the industry. These factors along with technological advances such as 3D printing technology and mobile applications are expected to drive the drugs for rheumatoid arthritis industry.

The drugs for rheumatoid arthritis market is marginally consolidated with a few large players, dominating the market. Major players in the market include AbbVie, Eli Lilly F. Hoffmann-La Roche AG, Valeant Pharmaceuticals, Novartis and others.